Porter's Five Forces of Competition

Introduction Competition in the business environment and strategies for this competition have existed and developed for centuries but the true revolution in the strategic field has been recently made by Harvard professor and economist Michael E. Porter It was started. According to Porter, "Strategist strives to understand and respond to competition" (Porter, 2008), competition is often too narrow, management ignores almost any competitiveness of customers, suppliers, etc. ing. Market entrants, and the possibility of alternative products.

Porter's Five Power: The five competitive position models of Michael Porter offer a competitive advantage and a simple perspective to evaluate and analyze the strengths and positions of companies and companies. Industry structure and position within the industry is the foundation of Michael Porter's competitive strategy model. The "five power" chart represents the main idea of ​​Porter's competitive advantage theory. Negotiation from Supplier: Sometimes they have to provide partial loans for the former, as strong customers can force suppliers to offer discounts, postpay or preferential services at any time. For example, a huge supermarket chain has enjoyed huge bargaining power and massive purchasing power (C Murphy, 2005) (Thompson and Strickland, 2004).

Porter's five powers are focused on competition within the industry. Five great powers are involved to fully evaluate the competitiveness of the industry. These forces include companies in competitive industries, the power of buyers, the power of the seller, the threat of new entrants, and the threat the competitors produce alternatives. The market share concentration in the brand name of pharmaceutical manufacturing is moderate (moderate market share) (Oliver, 2017). As of 2017, the four major companies account for more than 40% of the industry's total revenue (Oliver, 2017). There are a couple of reasons that there are only four large companies that account for nearly half of the total industry revenue. The patent cliff obliges many brand pharmaceutical companies to strengthen their work by improving operational efficiency (Oliver, 2017)